Circulating soluble receptor for advanced glycation end product identifies patients with bicuspid aortic valve and associated aortopathies

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 10, 2014, Pages 2349-2357

  Branchetti, Emanuela ^a   Bavaria, Joseph E ^a   Grau, Juan B ^a   Shaw, Richard E ^b   Poggio, Paolo ^a   Lai, Eric K ^a   Desai, Nimesh D ^a   Gorman, Joseph H ^a   Gorman, Robert C ^a   Ferrari, Giovanni ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Advanced glyosylation end product receptor; Aortic aneurysm, thoracic; Bicuspid aortic valve

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ELASTIN; PROTEOGLYCAN; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR;

ADULT; AGED; AORTA DISEASE; AORTA VALVE; AORTA VALVE REPLACEMENT; ARTICLE; ASCENDING AORTA SURGERY; BICUSPID AORTIC VALVE; BODY SURFACE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN EXPRESSION; SURGICAL PATIENT; AORTIC DISEASES; BLOOD; BLOOD VESSEL TRANSPLANTATION; COMPLICATION; HEART VALVE DISEASES; HEART VALVE REPLACEMENT; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; UPREGULATION;

ADULT; AGED; AORTIC DISEASES; AORTIC VALVE; BIOLOGICAL MARKERS; BLOOD VESSEL PROSTHESIS IMPLANTATION; FEMALE; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; RETROSPECTIVE STUDIES; RISK FACTORS; UP-REGULATION;

EID: 84914170429     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303784     Document Type: Article

References (34)

1. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol. 2010;55:2789-2800. doi:10.1016/j.jacc.2009.12.068.
2. Evangelista A. Bicuspid aortic valve and aortic root disease. Curr Cardiol Rep. 2011;13:234-241. doi:10.1007/s11886-011-0175-4.
3. Wittwer C, Lehner J, Fersching D, Siegele B, Stoetzer OJ, Holdenrieder S. Methodological and preanalytical evaluation of a RAGE immunoassay. Anticancer Res. 2012;32:2075-2078.
4. Roberts WC, Ko JM, Hamilton C. Comparison of valve structure, valve weight, and severity of the valve obstruction in 1849 patients having isolated aortic valve replacement for aortic valve stenosis (with or without associated aortic regurgitation) studied at 3 different medical centers in 2 different time periods. Circulation. 2005;112:3919-3929.
5. Tanaka R, Yoshioka K, Niinuma H, Ohsawa S, Okabayashi H, Ehara S. Diagnostic value of cardiac CT in the evaluation of bicuspid aortic stenosis: comparison with echocardiography and operative findings. AJR Am J Roentgenol. 2010;195:895-899.
6. Parish LM, Gorman JH 3rd, Kahn S, Plappert T, St John-Sutton MG, Bavaria JE, Gorman RC. Aortic size in acute type A dissection: implications for preventive ascending aortic replacement. Eur J Cardiothorac Surg. 2009;35:941-945; discussion 945.
7. Friedman T, Mani A, Elefteriades JA. Bicuspid aortic valve: clinical approach and scientific review of a common clinical entity. Expert Rev Cardiovasc Ther. 2008;6:235-248.
8. Lewin MB, Otto CM. The bicuspid aortic valve: adverse outcomes from infancy to old age. Circulation. 2005;111:832-834.
9. Rajamannan NM. Bicuspid aortic valve disease: the role of oxidative stress in Lrp5 bone formation. Cardiovasc Pathol. 2011;20:168-176.
10. Fedak PWM. Clinical and Pathophysiological Implications of a Bicuspid Aortic Valve. Circulation. 2002;106:900-904.
11. Zegdi R, Ciobotaru V, Huerre C, Allam B, Bouabdallaoui N, Berrebi A, Florens E, Fabiani JN. Detecting aortic valve bicuspidy in patients with severe aortic valve stenosis: high diagnostic accuracy of colour Doppler transoesophageal echocardiography. Interact Cardiovasc Thorac Surg. 2013;16:16-20.
12. Hiratzka LF, Bakris GL, Beckman JA, et al. American College of Cardiology Foundation, Guidelines AHATFOP, Surgery AAFT, Radiology ACO, Association AS, Anesthesiologists SOC, Interventions SFCAA, Radiology SOI, Surgeons SOT, Medicine SFV, Imaging NASFC. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. JAC. 2010;55:e27-e129.
13. Pacini D, Leone O, Turci S, Camurri N, Giunchi F, Martinelli GN, Di Bartolomeo R. Incidence, etiology, histologic findings, and course of thoracic inflammatory aortopathies. Ann Thorac Surg. 2008;86:1518-1523.
14. Ikonomidis JS, Ruddy JM, Benton SM Jr, Arroyo J, Brinsa TA, Stroud RE, Zeeshan A, Bavaria JE, Gorman JH 3rd, Gorman RC, Spinale FG, Jones JA. Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg. 2012;93:457-463.
15. Yan SF. Glycation, Inflammation, and RAGE: A Scaffold for the Macrovascular Complications of Diabetes and Beyond. Circ Res. 2003;93:1159-1169.
16. Lindsay ME, Dietz HC. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature. 2011;473:308-316.
17. Mautner GC, Mautner SL, Cannon RO 3rd, Hunsberger SA, Roberts WC. Clinical factors useful in predicting aortic valve structure in patients > 40 years of age with isolated valvular aortic stenosis. Am J Cardiol. 1993;72:194-198.
18. Michelena HI, Khanna AD, Mahoney D, Margaryan E, Topilsky Y, Suri RM, Eidem B, Edwards WD, Sundt TM 3rd, Enriquez-Sarano M. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA. 2011;306:1104-1112.
19. Parolari A, Tremoli E, Songia P, Pilozzi A, Di Bartolomeo R, Alamanni F, Mestres CA, Pacini D. Biological features of thoracic aortic diseases. Where are we now, where are we heading to: established and emerging biomarkers and molecular pathways. Eur J Cardiothorac Surg. 2013;44:9-23.
20. Ayad RF, Grayburn PA, Ko JM, Filardo G, Roberts WC. Accuracy of two-dimensional echocardiography in determining aortic valve structure in patients >50 years of age having aortic valve replacement for aortic stenosis. Am J Cardiol. 2011;108:1589-1599.
21. Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L. miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. Circ Cardiovasc Genet. 2011;4:197-205.
22. LeMaire SA, Wang X, Wilks JA, Carter SA, Wen S, Won T, Leonardelli D, Anand G, Conklin LD, Wang XL, Thompson RW, Coselli JS. Matrix metalloproteinases in ascending aortic aneurysms: bicuspid versus trileaflet aortic valves. J Surg Res. 2005;123:40-48.
23. Kang H, Hata A. MicroRNA regulation of smooth muscle gene expression and phenotype. Curr Opin Hematol. 2012;19:224-231.
24. Cotrufo M, Della Corte A, De Santo LS, Quarto C, De Feo M, Romano G, Amarelli C, Scardone M, Di Meglio F, Guerra G, Scarano M, Vitale S, Castaldo C, Montagnani S. Different patterns of extracellular matrix protein expression in the convexity and the concavity of the dilated aorta with bicuspid aortic valve: preliminary results. J Thorac Cardiovasc Surg. 2005;130:504-511.
25. Davis-Dusenbery BN, Chan MC, Reno KE, Weisman AS, Layne MD, Lagna G, Hata A. down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J Biol Chem. 2011;286:28097-28110.
26. Davies RR, Kaple RK, Mandapati D, Gallo A, Botta DM Jr, Elefteriades JA, Coady MA. Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann Thorac Surg. 2007;83:1338-1344.
27. Fedak PW, de Sa MP, Verma S, Nili N, Kazemian P, Butany J, Strauss BH, Weisel RD, David TE. Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg. 2003;126:797-806.
28. Elefteriades JA. Reasons to Investigate the Soluble Receptor for Advanced Glycation End-Product (sRAGE) Pathway in Aortic Disease. aorta. 2013:210.
29. Barlovic DP, Thomas MC, Jandeleit-Dahm K. Cardiovascular disease: what's all the AGE/RAGE about? Cardiovasc Hematol Disord Drug Targets. 2010;10:7-15.
30. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KAM. RAGE biology, atherosclerosis and diabetes. Clin Sci. 2011;121:43-55.
31. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498:99-111.
32. Das D, Gawdzik J, Dellefave-Castillo L, McNally EM, Husain A, Raman J, Hofmann Bowman MA. S100A12 expression in thoracic aortic aneurysm is associated with increased risk of dissection and perioperative complications. J Am Coll Cardiol. 2012;60:775-785.
33. Schmid FX, Bielenberg K, Schneider A, Haussler A, Keyser A, Birnbaum D. Ascending aortic aneurysm associated with bicuspid and tricuspid aortic valve: involvement and clinical relevance of smooth muscle cell apoptosis and expression of cell death-initiating proteins. Eur J Cardiothorac Surg. 2003;23:537-543.
34. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108:949-955.